BioPharma Dive - Latest News

New Akeso, Summit data stir debate on PD-1/VEGF drugs

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference wasn’t statistically significant.

Apr 28, 2025 - 15:57
 0
New Akeso, Summit data stir debate on PD-1/VEGF drugs

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference wasn’t statistically significant.

Read More

Tags:

Previous Article

Regulatory tracker: EU's CHMP signs off on drugs from Amgen, Vertex, Jazz and more

Next Article

STAT+: Capricor Therapeutics forges ahead with FDA on Duchenne drug, despite pol...

Related Posts

How integrated real-world data helps identify and improve outcomes for rare disease patients

How integrated real-world data helps identify and impro...

Apr 28, 2025  0

Former Neumora CEO to lead Galapagos spinout

Former Neumora CEO to lead Galapagos spinout

Apr 22, 2025  0

Merck takes $200M tariff hit, trimming its gross profits

Merck takes $200M tariff hit, trimming its gross profits

Apr 24, 2025  0